Summary: Reflection on portfolio performance, focus on long-term gains for 2025.
From Nasdaq: 2024-12-21 04:05:00
As we approach the end of the year, it’s time to reflect on your portfolio’s performance and plan for 2025. With triple-digit gains across all indexes, the right mix of stocks could make next year a winner. Focus on long-term gains, even if your portfolio didn’t perform as expected this year.
Nvidia (NASDAQ: NVDA) has had a stellar year, soaring over 160%. With the Blackwell architecture ramping up production, revenue is expected to increase significantly in the first quarter. Priced reasonably at 43x forward earnings estimates, Nvidia’s commitment to innovation keeps it ahead of competitors.
Pfizer (NYSE: PFE) is shifting focus to new products, launching 19 in 18 months. The company aims to double the number of patients taking its oncology drugs and launch eight or more blockbuster oncology medicines by 2030. This new wave of growth makes it a compelling stock to consider.
Viking Therapeutics (NASDAQ: VKTX) is entering phase 3 trials with VK2735, a potential blockbuster in the obesity treatment market. Positive clinical trial data could drive the stock higher in 2025, with the company poised for growth in a market with strong demand for new treatments.
Amazon (NASDAQ: AMZN) is leveraging AI to enhance its e-commerce operations and drive revenue growth. Lowering costs and improving operations through AI, Amazon is a leader in e-commerce, cloud computing, and now artificial intelligence. With AWS reporting $110 billion annualized revenue, Amazon is set for dominance in AI.
Etsy (NASDAQ: ETSY) struggled during times of higher inflation but is poised for a comeback with increased consumer spending. With a capital-light business model and 90% of EBITDA converted into free cash flow, Etsy is an attractive stock trading at a low forward earnings multiple.
Vertex Pharmaceuticals (NASDAQ: VRTX) dominates the cystic fibrosis treatment market and is expanding into new areas. With potential regulatory approval for suzetrigine, a drug for acute pain, Vertex sees significant growth opportunities in the near future.
CrowdStrike (NASDAQ: CRWD) faced challenges with a faulty software update but is seeing continued growth in annual recurring revenue. Despite the impact of the outage, customers remain loyal, and the company expects growth to resume by late next year.
Abbott Laboratories (NYSE: ABT) offers stability with diverse businesses and consistent dividend payments. With a range of operations, Abbott can navigate headwinds in one area with growth in others, making it a solid addition to any portfolio.
American Express (NYSE: AXP) targets a new generation of consumers with record revenue and growth in card fee revenue. As millennial and Gen-Z customers drive growth, American Express’s premium market position continues to be a winning strategy.
Palantir Technologies (NASDAQ: PLTR) is a leader in AI-driven software, with strong growth in commercial and government revenue. With sales to commercial customers taking off, Palantir’s stock could have significant upside potential for growth investors in 2025.
Read more at Nasdaq: My Top 10 Stocks to Buy for 2025